Wu, J., Yan, Z., Burcher, K., Han, Z., Nikiforov, M., Vuligonda, V., … Kang, Y. (2025). RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy. In Blood (Vol. 146, pp. 3950–3950). American Society of Hematology. https://doi.org/10.1182/blood-2025-3950

Wu, Jian, Zhibo Yan, Kimberly Burcher, Zhannan Han, Mikhail Nikiforov, Vidyasagar Vuligonda, Martin Sanders, and Yubin Kang. “RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy.” In Blood, 146:3950–3950. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-3950.

Wu J, Yan Z, Burcher K, Han Z, Nikiforov M, Vuligonda V, et al. RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy. In: Blood. American Society of Hematology; 2025. p. 3950–3950.

Wu, Jian, et al. “RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 3950–3950. Crossref, doi:10.1182/blood-2025-3950.

Wu J, Yan Z, Burcher K, Han Z, Nikiforov M, Vuligonda V, Sanders M, Kang Y. RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy. Blood. American Society of Hematology; 2025. p. 3950–3950.